A. Mita

R. Govindan, S. Ou, Weiwei Tan, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Isolation of isoflavonoids possessing antioxidant activity from the fermentation broth of Streptomyces sp.

S. Ōmura, A. Mita, Y. Takahashi, 1989, The Journal of antibiotics.

Structural study of isoflavonoids possessing antioxidant activity isolated from the fermentation broth of Streptomyces sp.

S. Ōmura, A. Mita, K. Komiyama, 1989, The Journal of antibiotics.

Structure-activity relationship of a novel antitumor ansamycin antibiotic trienomycin A and related compounds.

S. Ōmura, A. Mita, K. Komiyama, 1988, The Journal of antibiotics.

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

R. Doebele, E. Berge, D. Camidge, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma

T. MacDonald, K. Ligon, Yoon-Jae Cho, 2014, Clinical Cancer Research.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

Jennifer L Moseley, L. Chirieac, G. Shapiro, 2017, British Journal of Cancer.

Treatment at high‐volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer

M. Luu, A. Ho, Z. Zumsteg, 2017, Cancer.

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

D. Mahalingam, M. Mita, A. Mita, 2011, Targeted Oncology.

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

M. Mita, A. Mita, K. Sankhala, 2011, Targeted Oncology.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

C. Shapiro, M. Mita, A. Mita, 2014, Clinical breast cancer.

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.

L. Chirieac, G. Shapiro, S. Rodig, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

A. Tolcher, A. Mita, E. Rowinsky, 2010, Clinical Cancer Research.

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

M. Mita, A. Mita, J. Gong, 2016, World journal of methodology.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

B. Taylor, M. Berger, S. Chandarlapaty, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

A. Ravaud, K. Kelly, T. Stinchcombe, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.

M. Mita, A. Mita, E. Rowinsky, 2004, Clinical colorectal cancer.

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

B. Mellado, J. Machiels, L. Dirix, 2017, European journal of cancer.

Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States.

M. Goodman, N. Lee, A. Ho, 2016, JAMA oncology.

Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer

A. Ho, J. V. Van Eyk, Z. Zumsteg, 2017, JAMA oncology.

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Alain C. Mita, Francis J. Giles, F. Giles, 2008, Clinical Cancer Research.

Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer

R. Figlin, J. Xu, S. Alkan, 2020, Targeted Oncology.

Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics

M. Mita, A. Mita, Y. Linhares, 2017, Targeted Oncology.

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

A. Tolcher, T. Mays, A. Patnaik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications.

M. Luu, A. Ho, Z. Zumsteg, 2018, European journal of cancer.

Apoptosis: mechanisms and implications for cancer therapeutics

A. Tolcher, M. Mita, A. Mita, 2006, Targeted Oncology.

Targeting the mTOR pathway using deforolimus in cancer therapy.

Francis J Giles, F. Giles, D. Mahalingam, 2009, Future oncology.

Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.

F. Giles, D. Mahalingam, M. Mita, 2009, Current problems in cancer.

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

W. Guo, R. Kurzrock, F. Janku, 2017, Investigational New Drugs.

Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus

M. Mita, A. Mita, J. Carew, 2015, Molecular Cancer Therapeutics.

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Sabrina Smith, F. Giles, D. Mahalingam, 2009, Clinical Cancer Research.

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

F. Giles, M. Mita, A. Mita, 2008, Expert opinion on investigational drugs.

Mammalian target of rapamycin: a new molecular target for breast cancer.

M. Mita, A. Mita, E. Rowinsky, 2003, Clinical breast cancer.

A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies.

A. Lockhart, A. Mita, E. Rowinsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

K. Kelly, A. Heydebreck, J. Grewal, 2019, JAMA oncology.

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas

E. Ashton, E. Heath, P. LoRusso, 2010, Clinical Cancer Research.

Lymphomas Plinabulin ( NPI-2358 ) in Patients with Solid Tumors or Phase 1 First-inHuman Trial of the Vascular Disrupting Agent

E. Ashton, E. Heath, P. LoRusso, 2010 .

Cancer Therapy : Clinical Phase 1 First-inHuman Trial of the Vascular Disrupting Agent Plinabulin ( NPI-2358 ) in Patients with Solid Tumors or Lymphomas

E. Ashton, E. Heath, P. LoRusso, 2010 .

Perspectives in Head and Neck Medical Oncology.

A. Mita, E. Massarelli, K. Scher, 2018, Cancer treatment and research.

Predictors of survival in head and neck mucosal melanoma.

A. Ho, Z. Zumsteg, A. Mita, 2017, Oral oncology.

Facility Volume and Survival in Nasopharyngeal Carcinoma.

M. Luu, N. Lee, A. Ho, 2018, International journal of radiation oncology, biology, physics.

Quantitative survival impact of composite treatment delays in head and neck cancer

A. Ho, Z. Zumsteg, M. Tighiouart, 2018, Cancer.

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

A. Tolcher, J. Michalek, M. Beeram, 2010, Cancer Chemotherapy and Pharmacology.

DEVELOPMENT OF A FIVE-GENE HEDGEHOG SIGNATURE AS A PATIENT PRESELECTION TOOL FOR HEDGEHOG PATHWAY-TARGETED THERAPY IN MEDULLOBLASTOMA

Keith L. Ligon, Douglas Robinson, Jordi Rodon, 2013 .

A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma

A. Tolcher, P. LoRusso, K. Papadopoulos, 2020, Clinical Cancer Research.

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

J. Nemunaitis, T. Meyer, L. Paz-Ares, 2019, PloS one.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

J. Berlin, H. Wakelee, D. Rasco, 2019, Oncology.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J. Tabernero, A. Italiano, J. Soria, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

R. Govindan, A. Italiano, J. Tabernero, 2019, Clinical Cancer Research.

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.

J. Verweij, M. D. de Jonge, A. Mita, 2010, European journal of cancer.

The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs

J. Medin, J. Kok, O. Cuvillier, 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

A. Jimeno, Rui-Ru Ji, N. Dhani, 2023, Investigational New Drugs.

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

R. Dummer, J. Baselga, H. Tawbi, 2014, Clinical Cancer Research.

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation

Peng Huang, F. Giles, D. Mahalingam, 2009, Journal of cellular and molecular medicine.

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma

A. Tolcher, G. Weiss, C. Takimoto, 2007, Cancer Chemotherapy and Pharmacology.

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

M. Hidalgo, M. Mita, A. Mita, 2009, Clinical Cancer Research.

A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors.

J. Baselga, H. Tawbi, J. Dey, 2010 .

mTOR Inhibition for Cancer Therapy: Past, Present and Future

M. Mita, A. Mita, E. Rowinsky, 2016 .

Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

I. Puzanov, E. Chan, J. Gilbert, 2012, Clinical Cancer Research.

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

A. Tolcher, E. Rasmussen, C. Takimoto, 2010, Clinical Cancer Research.

Reovirus-based therapy for cancer

M. Coffey, F. Giles, M. Mita, 2009, Expert opinion on biological therapy.

Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation.

R. Dummer, H. Tawbi, J. Dey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

David A. Smith, J. Nemunaitis, A. Mita, 2014, Cancer Immunology, Immunotherapy.

Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC)

G. Hudes, D. Quinn, A. Mita, 2007 .

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

J. Dancey, Helen X. Chen, A. Tolcher, 2009, Cancer Chemotherapy and Pharmacology.

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

A. Brenner, R. Kurzrock, S. Moulder, 2011, Molecular Cancer Therapeutics.

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas

M. Mita, A. Mita, J. Carew, 2017, Oncotarget.

P3-115: Erlotinib (Tarcevar) “dosing–to–rash”: characterization of skin toxicity from a pilot phase II intra–patient dose–escalation study of E in previously treated patients with advanced non–small cell lung cancer (NSCLC)

J. Verweij, K. Papadopoulos, M. Mita, 2007 .

Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors

Jennifer L Moseley, A. Lockhart, M. Mita, 2014, Investigational New Drugs.

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Glen J Weiss, P. LoRusso, D. V. Von Hoff, 2016, Clinical Cancer Research.

Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.

M. Luu, A. Ho, Z. Zumsteg, 2019, Oral oncology.

Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification

M. Luu, A. Ho, Z. Zumsteg, 2018, Head & neck.

Nodal staging convergence for HPV− and HPV+ oropharyngeal carcinoma

M. Luu, A. Ho, Z. Zumsteg, 2021, Cancer.

Impact of concomitant chemoradiation on survival for patients with T1‐2N1 head and neck cancer

N. Lee, A. Ho, Z. Zumsteg, 2017, Cancer.

Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors.

D. McNeel, G. Daniels, A. Mita, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2019, Journal of Immunotherapy for Cancer.

Variations in the association of grade with survival across the head and neck cancer landscape

M. Luu, A. Ho, Z. Zumsteg, 2020, Head & neck.

407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

Y. Najjar, A. Shields, S. Hu-Lieskovan, 2020 .

Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2018, Clinical Trials.

Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.

P. LoRusso, M. Mita, A. Mita, 2011, Current drug targets.

A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G)

L. Rosen, A. Mita, F. Capilla, 2008 .

Impact of insurance on survival in patients < 65 with head & neck cancer treated with radiotherapy

M. Luu, A. Ho, Z. Zumsteg, 2020, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation

M. Luu, A. Ho, Z. Zumsteg, 2019, Annals of Oncology.

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

A. Ravaud, K. Kelly, T. Stinchcombe, 2016 .

Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

B. Taylor, S. Chandarlapaty, J. Baselga, 2018 .

AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors

E. Rasmussen, C. Takimoto, P. LoRusso, 2007 .

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Patrick Schöffski, Alain C. Mita, Josep Tabernero, 2012, Clinical Cancer Research.

6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies

A. Mita, P. Soulié, E. Brain, 2005, Journal of Cancer Research and Clinical Oncology.

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

D. Camidge, J. Spicer, A. Mita, 2010 .

The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors

A. Tolcher, R. Lutz, A. Mita, 2008 .

Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update.

T. Garyantes, S. Patel, C. Muller, 2022, Journal of Clinical Oncology.

Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.

J. McQuade, T. Garyantes, P. LoRusso, 2021 .

Phase I evaluation of a 24-h infusion of TAS-106 every 3 weeks (wks) in patients (pts) with solid tumors

A. Tolcher, C. Takimoto, M. Mita, 2007 .

Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results.

D. Benson, A. Mita, M. Smith, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting Pathologic Lymph Node Positivity in cN0 Pharynx and Larynx Cancers

M. Luu, A. Ho, Z. Zumsteg, 2022, The Laryngoscope.

Comparative impact of grade on mortality across salivary cancers: A novel, unifying staging system

M. Luu, A. Ho, Z. Zumsteg, 2023, Head & neck.

Are we ready to move away from nature? The rapamycin story

M. Mita, A. Mita, 2011, Targeted Oncology.

523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors

Y. Najjar, A. Shields, S. Hu-Lieskovan, 2021, Journal for ImmunoTherapy of Cancer.

Cancer Therapy: Clinical Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

M. Hidalgo, M. Mita, A. Mita, 2009 .

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

A. Lockhart, J. Mier, C. Hsueh, 2017, Cancer Chemotherapy and Pharmacology.

Bromodomain inhibitors a decade later: a promise unfulfilled?

M. Mita, A. Mita, 2020, British Journal of Cancer.

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies.

A. Tolcher, M. Mita, C. Bedrosian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 4818: The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy

T. MacDonald, K. Ligon, B. Geoerger, 2012 .

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

A. Tolcher, J. Verweij, K. Papadopoulos, 2011, British Journal of Cancer.

Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts

Suzanne F. Jones, A. Tinker, A. Oza, 2019, Clinical Trials.

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Suzanne F. Jones, A. Tinker, A. Oza, 2023, Targeted Oncology.

Heat shock proteins: a potential anticancer target.

C. Takimoto, M. Mita, A. Mita, 2011, Current drug targets.

Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging.

A. Tolcher, G. Weiss, M. Beeram, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma.

M. Luu, A. Ho, Z. Zumsteg, 2020, JAMA oncology.

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

R. Dummer, J. Baselga, H. Tawbi, 2014, Clinical Cancer Research.

Combined autophagy and HDAC inhibition

T. Curiel, F. Giles, D. Mahalingam, 2014, Autophagy.

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma.

A. Tolcher, J. Michalek, M. Beeram, 2010 .

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

S. Tavazoie, M. Postow, M. Mita, 2018 .

A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors

A. Tolcher, A. Patnaik, M. Mita, 2007 .

Phase I/II Study to Assess the Safety, Pharmacokinetics (PK) and Efficacy of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Carboplatin/Etoposide in Patients with Solid Tumors Including Small-Cell Lung Cancer (SCLC)

A. Argiris, J. Bendell, A. Mita, 2012 .

514 POSTER A novel dosing strategy based on plasma levels of CanAg in a Phase II study of IMGN242 (HUC242-DM4) in gastric cancer

A. Tolcher, R. Lutz, A. Mita, 2008 .

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

J. Baselga, C. Takimoto, J. Tabernero, 2012, Clinical Cancer Research.

Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States.

M. Goodman, N. Lee, A. Ho, 2016, JAMA oncology.

A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors.

A. Tolcher, A. Mita, S. Antonia, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.

T. Garyantes, S. Patel, A. Shoushtari, 2023, Journal of Clinical Oncology.

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

A. Tolcher, W. Tap, F. Haluska, 2013, Annals of Oncology.

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

A. Tolcher, W. Tap, F. Haluska, 2013, Annals of Oncology.

Targeting the mTOR pathway using deforolimus in cancer therapy.

F. Giles, D. Mahalingam, M. Mita, 2009, Future Oncology.

Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors.

E. Hersh, A. Mita, E. Rowinsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.

M. Luu, A. Ho, Z. Zumsteg, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

409 AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies — a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study

A. Tolcher, M. Mita, C. Bedrosian, 2004 .

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .

Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.

M. Luu, A. Ho, Z. Zumsteg, 2019, Oral oncology.

Stage I HPV‐positive oropharyngeal cancer: Should all patients receive similar treatments?

M. Luu, A. Ho, Z. Zumsteg, 2019, Cancer.